SCHEMBL2677401

SCHEMBL2677401

CS(=O)(=O)c1ccc(C(C[C@H]2C[C@@H](F)[C@@H](F)C2)C(=O)Nc2nccs2)cc1

nearest known ligand 0.79

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 15/20 0.79
▸ KCNH2 Q12809 1/20 0.61
▸ FFAR2 O15552 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676652 1.00 GCK (0.79) GCKKCNH2FFAR2
SCHEMBL2677833 1.00 GCK (0.79) GCKKCNH2FFAR2
SCHEMBL2676653 1.00 GCK (0.79) GCKKCNH2FFAR2
SCHEMBL2677827 1.00 GCK (0.79) GCKKCNH2FFAR2
SCHEMBL2676257 1.00 GCK (0.79) GCKKCNH2FFAR2
SCHEMBL2676254 1.00 GCK (0.79) GCKKCNH2FFAR2
SCHEMBL2511547 0.89 GCK (0.78) GCKKCNH2FFAR2
SCHEMBL2512192 0.89 GCK (0.78) GCKKCNH2FFAR2
SCHEMBL2511545 0.89 GCK (0.78) GCKKCNH2FFAR2
Ro-281675 SCHEMBL2646000 0.88 GCK (1.00) GCKKCNH2FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2116535-B1 GLUCOKINASE-ACTIVATING SUBSTANCE KYORIN SEIYAKU KK (JP) 2014-06-11 — — EP claimed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 — — US claimed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 — — US claimed
EP-2116535-B1 GLUCOKINASE-ACTIVATING SUBSTANCE KYORIN SEIYAKU KK (JP) 2014-06-11 — — EP disclosed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 — — US disclosed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016304-A1 GLUCOKINASE ACTIVATOR GCK, GCKR, GALK1 GCK 1/4885KCNH2 342/4885FFAR2 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback